betamethasone acibutate

Betamethasone acibutate is a synthetic glucocorticoid corticosteroid ester with potent anti-inflammatory and immunosuppressive properties. As a prodrug of betamethasone, it functions as an agonist of the glucocorticoid receptor, modulating gene transcription to inhibit the production of pro-inflammatory cytokines and mediators. In clinical research, betamethasone formulations are evaluated for the treatment of inflammatory conditions such as rheumatoid arthritis and active synovitis. Specifically, the Panguian trial (NCT03440190), conducted by the Videncenter for Reumatologi og Rygsygdomme at Rigshospitalet in Denmark, compared ultrasound-guided intra-articular injections against intramuscular injections of betamethasone to achieve synovitis remission. Although the Panguian trial specifically utilized a combination of betamethasone acetate and betamethasone sodium phosphate (Celestone Soluspan), the name 'betamethasone acebutate' is a recognized synonym for the acibutate ester in various chemical and pharmaceutical databases.

Other names

betamethasone acebutatebetamethasone acetate-isobutyratebetamethasone 21-acetate 17-isobutyratebetamethasone21-acetate 17-isobutyratebetamethasone-21-acetate 17-isobutyrate